{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:19:14Z","timestamp":1794442754777,"version":"4.9.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck","id":[{"id":"https:\/\/ror.org\/01tvm6f46","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Managing atrial fibrillation in kidney transplant patients poses a challenge for both nephrologists and cardiologists. Data regarding the safety and efficacy of catheter ablation in this patient\u2019s cohort is scarce.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>\n                      In this two-center prospective study, we included all consecutive kidney transplant patients who underwent atrial fibrillation ablation between April 2017 and March 2022. A 1:3 propensity score matching created a control group of non-transplant AF patients undergoing ablation. We included 16 kidney transplant patients and 48 matched controls. Ablation was successful in all patients. The periprocedural complication rate (6.3% in the kidney transplant group vs. 6.3% in the control group,\n                      <jats:italic>p<\/jats:italic>\n                      value\u2009=\u20091) did not differ between the two groups. One transplant patient experienced graft dysfunction after a complication. At 18\u00a0months, AF recurrence-fee rates were 69% in the transplant group and 70.1% in controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.95). By the last follow-up, all transplant patients had discontinued antiarrhythmic drugs, while 19.6% of the patients in the control group were treated with antiarrhythmic drugs (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.09). Kidney function in the transplant group remained stable (eGFR 32 [23.8, 40.5] ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      before vs. 34 [29.8, 38] ml\/min\/1.73 m\n                      <jats:sup>2<\/jats:sup>\n                      at last follow up,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.93).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrates that catheter ablation is a viable option for treating AF in kidney transplant patients, with comparable outcomes to non-transplanted individuals. Discontinuing antiarrhythmic drugs reduces drug interaction risks, but minimizing procedural complications remains critical to preserving graft function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s10840-025-02006-x","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T04:42:15Z","timestamp":1740717735000},"page":"1017-1026","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety and efficacy of atrial fibrillation ablation in kidney transplant patients"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4811-4464","authenticated-orcid":false,"given":"Ahmad","family":"Keelani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8437-0222","authenticated-orcid":false,"given":"Lorenzo","family":"Bartoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Gasperetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sorin","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Traub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6867-914X","authenticated-orcid":false,"given":"Huong-Lan","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Feher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Sciacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2716-7527","authenticated-orcid":false,"given":"Martin","family":"Nitschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Vogler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Eitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Forleo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-8097","authenticated-orcid":false,"given":"Christian-H.","family":"Heeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0122-7130","authenticated-orcid":false,"given":"Roland R.","family":"Tilz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"2006_CR1","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725\u201330.","journal-title":"N Engl J Med"},{"key":"2006_CR2","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1093\/ndt\/gfz053","volume":"34","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Mathew RO, Parasuraman R, et al. Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrol Dial Transplant. 2019;34:760\u201373.","journal-title":"Nephrol Dial Transplant"},{"key":"2006_CR3","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","volume":"39","author":"MP Turakhia","year":"2018","unstructured":"Turakhia MP, Blankestijn PJ, Carrero JJ, et al. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: Improving global outcomes (KDIGO) Controversies conference. Eur Heart J. 2018;39:2314\u201325.","journal-title":"Eur Heart J"},{"key":"2006_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/CIRCULATIONAHA.112.123992","volume":"127","author":"N Bansal","year":"2013","unstructured":"Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013;127:569\u201374.","journal-title":"Circulation"},{"key":"2006_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.2215\/CJN.10921015","volume":"11","author":"N Bansal","year":"2016","unstructured":"Bansal N, Xie D, Tao K, et al. Atrial fibrillation and risk of ESRD in adults with CKD. Clin J Am Soc Nephrol. 2016;11:1189\u201396.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2006_CR6","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1111\/ajt.12197","volume":"13","author":"CR Lenihan","year":"2013","unstructured":"Lenihan CR, Montez-Rath ME, Scandling JD, et al. Outcomes after kidney transplantation of patients previously diagnosed with atrial fibrillation. Am J Transplant. 2013;13:1566\u201375.","journal-title":"Am J Transplant"},{"key":"2006_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2215\/CJN.00920805","volume":"1","author":"KL Lentine","year":"2006","unstructured":"Lentine KL, Schnitzler MA, Abbott KC, et al. Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol. 2006;1:288\u201396.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"2006_CR8","doi-asserted-by":"publisher","first-page":"euae043","DOI":"10.1093\/europace\/euae043","volume":"26","author":"S Tzeis","year":"2024","unstructured":"Tzeis S, Gerstenfeld EP, Kalman J, et al. 2024 European Heart Rhythm Association\/Heart Rhythm Society\/Asia Pacific Heart Rhythm Society\/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2024;26(4):euae043.","journal-title":"Europace"},{"issue":"21","key":"2006_CR9","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1016\/j.jacc.2023.03.418","volume":"81","author":"K Benali","year":"2023","unstructured":"Benali K, Khairy P, Hammache N, et al. Procedure-related complications of catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2023;81(21):2089\u201399. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.418.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2006_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.hrthm.2024.03.043","volume":"21","author":"CP Oates","year":"2024","unstructured":"Oates CP, Basyal B, Whang W, et al. Trends in safety of catheter-based electrophysiology procedures in the last 2 decades: a meta-analysis. Heart Rhythm. 2024;21(9):1718\u201326. https:\/\/doi.org\/10.1016\/j.hrthm.2024.03.043.","journal-title":"Heart Rhythm"},{"key":"2006_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825\u201330.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2006_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.kint.2021.06.028","volume":"100","author":"NH Lameire","year":"2021","unstructured":"Lameire NH, Levin A, Kellum JA, et al. Harmonizing acute and chronic kidney disease definition and classification: report of a kidney disease: improving global outcomes (KDIGO) consensus conference. Kidney Int. 2021;100(3):516\u201326.","journal-title":"Kidney Int"},{"issue":"6","key":"2006_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1097\/TP.0000000000004452","volume":"107","author":"TAJ van den Berg","year":"2023","unstructured":"van den Berg TAJ, Nieuwenhuijs-Moeke GJ, Lisman T, et al. Pathophysiological changes in the hemostatic system and antithrombotic management in kidney transplant recipients. Transplantation. 2023;107(6):1248\u201357.","journal-title":"Transplantation"},{"key":"2006_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.5603\/CJ.a2020.0036","volume":"29","author":"M Budnik","year":"2022","unstructured":"Budnik M, Gawa\u0142ko M, Gorczyca I, et al. Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease. Cardiol J. 2022;29:205\u201315.","journal-title":"Cardiol J"},{"key":"2006_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1161\/STROKEAHA.114.006881","volume":"46","author":"WT Zeng","year":"2015","unstructured":"Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke. 2015;46:157\u201363.","journal-title":"Stroke"},{"key":"2006_CR16","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","volume":"30","author":"P Masson","year":"2015","unstructured":"Masson P, Webster AC, Hong M, et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30:1162\u20139.","journal-title":"Nephrol Dial Transplant"},{"key":"2006_CR17","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","volume":"74","author":"S Kumar","year":"2019","unstructured":"Kumar S, Lim E, Covic A, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week. J Am Coll Cardiol. 2019;74:2204\u2013221517.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2006_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1093\/europace\/euz358","volume":"22","author":"TS Potpara","year":"2020","unstructured":"Potpara TS, Ferro C, Lip GYH, et al. Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association\/European Dialysis and Transplantation Association (ERA\/EDTA) physician-based survey. Europace. 2020;22(3):496\u2013505.","journal-title":"Europace"},{"key":"2006_CR19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.amjcard.2012.02.061","volume":"110","author":"J Chen","year":"2012","unstructured":"Chen J, Mohler ER III, Xie D, et al. Risk factors for peripheral arterial disease among patients with chronic kidney disease. Am J Cardiol. 2012;110:136\u201341.","journal-title":"Am J Cardiol"},{"issue":"11","key":"2006_CR20","doi-asserted-by":"publisher","first-page":"euad315","DOI":"10.1093\/europace\/euad315","volume":"25","author":"DG Della Rocca","year":"2023","unstructured":"Della Rocca DG, Magnocavallo M, Van Niekerk CJ, et al. Prognostic value of chronic kidney disease in patients undergoing left atrial appendage occlusion. Europace. 2023;25(11):euad315.","journal-title":"Europace."},{"issue":"4","key":"2006_CR21","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1093\/europace\/euad056","volume":"25","author":"T Yamamoto","year":"2023","unstructured":"Yamamoto T, Miyazaki S, Tanaka Y, et al. Peri-procedural anticoagulation in patients with end-stage kidney disease undergoing atrial fibrillation ablation: results from the multicentre end-stage kidney disease-atrial fibrillation ablation registry. Europace. 2023;25(4):1400\u20137.","journal-title":"Europace"},{"key":"2006_CR22","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1111\/jce.14775","volume":"31","author":"X Su","year":"2020","unstructured":"Su X, Zhao X, Long DY, et al. Safety and efficacy of catheter ablation for atrial fibrillation in abdominal solid organ (renal and hepatic) transplant recipients: a single-center pilot experience. J Cardiovasc Electrophysiol. 2020;31:3141\u20139.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2006_CR23","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1540-8159.2012.03350.x","volume":"35","author":"A Berkowitsch","year":"2012","unstructured":"Berkowitsch A, Kuniss M, Greiss H, et al. Impact of impaired renal function and metabolic syndrome on the recurrence of atrial fibrillation after catheter ablation: a long term follow-up. Pacing Clin Electrophysiol. 2012;35:532\u201343.","journal-title":"Pacing Clin Electrophysiol"},{"key":"2006_CR24","first-page":"126","volume":"9","author":"G Boriani","year":"2022","unstructured":"Boriani G, Iacopino S, Arena G, et al. Chronic kidney disease with mild and mild to moderate reduction in renal function and long-term recurrences of atrial fibrillation after pulmonary vein cryoballoon ablation. J Cardiovasc Dev Dis. 2022;9:126.","journal-title":"J Cardiovasc Dev Dis"},{"key":"2006_CR25","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.2174\/1381612824666180829112019","volume":"24","author":"I Diemberger","year":"2018","unstructured":"Diemberger I, Genovesi S, Massaro G, et al. Meta-analysis of clinical outcomes of electrical cardioversion and catheter ablation in patients with atrial fibrillation and chronic kidney disease. Curr Pharm Des. 2018;24:2794\u2013801.","journal-title":"Curr Pharm Des"},{"key":"2006_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gft233","volume":"29","author":"M Hayashi","year":"2013","unstructured":"Hayashi M, Kaneko S, Shimano M, et al. Efficacy and safety of radiofrequency catheter ablation for atrial fibrillation in chronic hemodialysis patients. Nephrol Dial Transplant. 2013;29:160\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2006_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/anec.12225","volume":"20","author":"B Ikitimur","year":"2015","unstructured":"Ikitimur B, Cosansu K, Karadag B, et al. Long-term impact of different immunosuppressive drugs on QT and PR intervals in renal transplant patients. Ann Noninvasive Electrocardiol. 2015;20(5):426\u201332.","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"2006_CR28","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1097\/TP.0b013e3181d2fed7","volume":"89","author":"CI Burger","year":"2010","unstructured":"Burger CI, Clase CM, Gangji AS. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation. 2010;89:1166\u20137.","journal-title":"Transplantation"},{"key":"2006_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.5414\/CNP70563","volume":"70","author":"K Kisters","year":"2008","unstructured":"Kisters K, Cziborra M, Funke C, et al. Amiodarone-tacrolimus interaction in kidney transplantation. Clin Nephrol. 2008;70:563.","journal-title":"Clin Nephrol"},{"key":"2006_CR30","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1097\/TP.0000000000000280","volume":"98","author":"M Marin-Casino","year":"2014","unstructured":"Marin-Casino M, P\u00e9rez-S\u00e1ez MJ, Crespo M, et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. Transplantation. 2014;98:e33\u20134.","journal-title":"Transplantation"},{"key":"2006_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/106002809302700506","volume":"27","author":"KK Chitwood","year":"1993","unstructured":"Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother. 1993;27:569\u201371.","journal-title":"Ann Pharmacother"},{"key":"2006_CR32","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/0002-8703(92)90848-P","volume":"123","author":"F Mamprin","year":"1992","unstructured":"Mamprin F, Mullins P, Graham T, et al. Amiodarone-cyclosporine interaction in cardiac transplantation. Am Heart J. 1992;123:1725\u20136.","journal-title":"Am Heart J"},{"issue":"5","key":"2006_CR33","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/heartjnl-2019-315792","volume":"106","author":"T Inohara","year":"2020","unstructured":"Inohara T, Holmes DN, Pieper K, et al. Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart. 2020;106(5):358\u201364.","journal-title":"Heart"},{"key":"2006_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/jce.12530","volume":"26","author":"L Navaravong","year":"2015","unstructured":"Navaravong L, Barakat M, Burgon N, et al. Improvement in estimated glomerular filtration rate in patients with chronic kidney disease undergoing catheter ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2015;26:21\u20137.","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2006_CR35","doi-asserted-by":"publisher","first-page":"e013204","DOI":"10.1161\/JAHA.119.013204","volume":"8","author":"JW Park","year":"2019","unstructured":"Park JW, Yang PS, Bae HJ, et al. Five-year change in the renal function after catheter ablation of atrial fibrillation. J Am Heart Assoc. 2019;8:e013204.","journal-title":"J Am Heart Assoc"},{"key":"2006_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hjc.2022.03.006","volume":"65","author":"M Schiavone","year":"2022","unstructured":"Schiavone M, Gasperetti A, Montemerlo E, et al. Long-term comparisons of atrial fibrillation ablation outcomes with a cryoballoon or laser-balloon: a propensity-matched analysis based on continuous rhythm monitoring. Hellenic J Cardiol. 2022;65:1\u20137.","journal-title":"Hellenic J Cardiol"},{"issue":"4","key":"2006_CR37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jacep.2023.12.008","volume":"10","author":"S Mohanty","year":"2024","unstructured":"Mohanty S, Casella M, Compagnucci P, et al. Acute kidney injury resulting from hemoglobinuria after pulsed-field ablation in atrial fibrillation: is it preventable? JACC Clin Electrophysiol. 2024;10(4):709\u201315.","journal-title":"JACC Clin Electrophysiol"},{"key":"2006_CR38","doi-asserted-by":"publisher","unstructured":"Chun KJ, Miklav\u010di\u010d D, Vlachos K et al State-of-the-art pulsed field ablation for cardiac arrhythmias: ongoing evolution and future perspective. Europace. 2024;26(6):euae134. https:\/\/doi.org\/10.1093\/europace\/euae134. Erratum in: Europace. 2024 Jul 2;26(7):euae182","DOI":"10.1093\/europace\/euae134"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-02006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-025-02006-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-025-02006-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T06:44:14Z","timestamp":1757141054000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-025-02006-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2006"],"URL":"https:\/\/doi.org\/10.1007\/s10840-025-02006-x","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LB received an educational grant through his institution from Biosense Webster. HLP received ravel grants from Cardiofocus, Abbott and Biosense Webster; educational grants: from Biosense Webster and Medtronic and speaker\u00b4s Honoraria from C.T.I. GmbH. CE received travel grants and research grants from Boston Scientific, Lifetech, Biosense Webster and Daiichi Sankyo and speaker honoraria from Boston Scientific, Lifetech, Biosense Webster, Abbott, C.T.I. GmbH and Doctrina Med. CHH received travel grants and research grants from Boston Scientific, Lifetech, Biosense Webster and Cardiofocus and speaker honoraria from Boston Scientific, Lifetech, Biosense Webster, Abbott, Cardiofocus and C.T.I. GmbH and Doctrina Med. RRT is a consultant for Boston Scientific, Biotronik and Biosense Webster and received speaker honoraria from Biosense Webster, Medtronic, Boston Scientific and Abbot Medical. KHK reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster outside the submitted work. KHK reports grants and personal fees from Abbott Vascular, Medtronic, Biosense Webster outside the submitted work. All other authors have no relevant disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}